Trials / Completed
CompletedNCT02993575
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion as Therapy to Patients With an Infection in the Intensive Care Unit (ICU)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine total and free flucloxacillin concentrations in 30 ICU patients, who will get continuous (n=10) or intermittent infusion (n=20) of flucloxacillin as standard care. Full pharmacokinetic curves will be taken for individual patients on the intermittent dosing regimen and limited sampling will be taken for individual patients on the continuous dosing regimen on day 2 and 4.
Detailed description
The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared to non-ICU patients. There is a substantial risk that present standard dosing regimens of antibiotics lead to suboptimal outcomes for patients on the ICU. To prevent the risk of inadequate dosing in critically ill patients, it is important to optimize dosing regimens in ICU patients. With this study the investigators will define pharmacokinetics of flucloxacillin in ICU patients and search for variables influencing pharmacokinetics. By using population modeling the investigators will simulate different dosing regimens, intermittent and continuous, and compare probability of target attainment between continuous and intermittent infusion. To be able to include 30 patients within the study duration, a multi-centre approach is necessary. Patients will receive standard care, as stated in the product characteristics or according to local protocols. Minimally invasive blood sampling for pharmacokinetic analysis will be retrieved through a central venous catheter or an arterial line. Full pharmacokinetic curves will be taken for individual patients on the intermittent dosing regimen and limited sampling will be taken for individual patients on the continuous dosing regimen on day 2 and 4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flucloxacillin | Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2018-03-01
- Completion
- 2018-04-01
- First posted
- 2016-12-15
- Last updated
- 2018-10-23
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02993575. Inclusion in this directory is not an endorsement.